SLE patients' PBMCs show extensive mitochondrial gene mutations and suppressed expression, exacerbated by inflammation
Background
Systemic lupus erythematosus (SLE) is a chronic, progressive autoimmune disease characterized by systemic immune complex deposition and a significant unmet need for effective therapies. Unlike other autoimmune conditions, SLE has fewer licensed drugs, highlighting the need for deeper understanding of its pathogenesis. Emerging evidence suggests mitochondrial dysfunction plays a crucial role in autoimmune diseases, with mitochondrial DNA (mtDNA) acting as a danger-associated molecular pattern (DAMP) when released, potentially driving inflammation. Investigating mitochondrial gene integrity and expression in SLE could uncover novel therapeutic targets.
Study Design
Researchers collected peripheral blood mononuclear cells (PBMCs) from female SLE patients and healthy controls. Mitochondrial DNA (mtDNA) from SLE PBMCs was sequenced using the HiSeq PE150 platform to identify mutations. mRNA and protein expression levels of frequently mutated mitochondrial genes were quantified via quantitative reverse transcription PCR and western blotting. To assess regulatory effects, cultured PBMCs were treated with lipopolysaccharide (LPS), tumor necrosis factor-α (TNF-α), or dexamethasone to simulate inflammatory and therapeutic conditions.
Results
The study identified a total of 589 mtDNA mutation sites in SLE patients' PBMCs. Among the 13 protein-coding mitochondrial genes, MT-ND5, MT-CYB, MT-CO1, MT-ND4, and MT-CO3 displayed the highest mutation frequencies. Expression analysis revealed significantly reduced mRNA and protein levels of these genes in SLE PBMCs compared to controls. This suppression was further exacerbated by inflammatory and therapeutic stimuli:
Stimulation with LPS, TNF-α, or dexamethasone led to additional decreases in the mRNA and protein expression of key mitochondrial genes in SLE PBMCs. These findings suggest a profound impact of SLE and its associated inflammatory environment on mitochondrial integrity and function, particularly affecting genes critical for oxidative phosphorylation.
Key Findings
- A total of 589 mtDNA mutation sites were detected in PBMCs from SLE patients.
MT-ND5,MT-CYB,MT-CO1,MT-ND4, andMT-CO3showed the highest mutation frequencies.- mRNA and protein levels of key mitochondrial genes were significantly reduced in SLE PBMCs.
- Inflammatory stimuli (LPS, TNF-α) further decreased mitochondrial gene expression in SLE PBMCs.
- Dexamethasone treatment also exacerbated the suppression of mitochondrial gene expression.
Why It Matters
This research highlights mitochondrial dysfunction as a significant contributor to SLE susceptibility and progression, offering a new avenue for therapeutic intervention. Understanding that inflammatory and therapeutic stimuli can further suppress mitochondrial gene expression suggests that current treatments might inadvertently exacerbate certain aspects of mitochondrial health. Targeting mitochondrial integrity or function could represent a novel strategy to manage SLE, potentially by protecting against mtDNA damage or boosting mitochondrial biogenesis. While this study is foundational, it moves us closer to identifying biomarkers for disease activity and developing therapies that support mitochondrial health in SLE patients, moving beyond broad immunosuppression.
sle
autoimmune-disease
mitochondrial-dysfunction
mt-nd5
gene-expression
inflammation